Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

Cystic Fibrosis Clinical Trial

Official title:

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03482960
• Other study ID #: 17-2569
• Secondary ID: XePFP2017
• Status: Completed
• Phase: Early Phase 1
• Start date: May 29, 2018
• Est. completion date: April 10, 2019

Study information

• Verified date: September 2020
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to compare the capabilities of two novel imaging techniques: polarized perfluorinated gas mixed with oxygen, and hyperpolarized xenon mixed with N2 to detect changes in lung ventilation using MRI.

Description:

The goal of this study is to compare the capabilities of two novel imaging techniques: conventional 'thermally' polarized perfluorinated gases (perfluoropropane, or PFP) mixed with oxygen, and hyperpolarized xenon (129Xe) mixed with N2 to detect changes in lung ventilation using magnetic resonance imaging (MRI). Although considerable work has been done internationally with hyperpolarized xenon MRI, the low availability and high cost of this technique is limiting. Perfluorinated gas MRI is an alternative that may in fact be a suitable, simpler alternative. PFP is commercially availability in large quantities, which allows multiple breath studies and thus provides the ability to analyze gas wash-in and wash-out kinetics. These endpoints may improve the investigators ability to detect ventilation abnormalities beyond the traditional "ventilation defect percentage" parameter obtained with 129Xe MRI. The commercial availability of PFP and lack of need for onsite hyperpolarization may also facilitate the transfer of this technology to other centers for the conduct of multicenter studies. The investigators hypothesize that 19F MRI will not be inferior to hyperpolarized xenon MRI in detection of ventilation defect percentages (VDP).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: April 10, 2019
• Est. primary completion date: April 9, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects with CF must meet all of the following inclusion criteria to be eligible for

enrollment:

1. Subjects must be at least 18 years of age;

2. Non-smokers (<10 pack year history and no active smoking in the past year);

3. Diagnosis of cystic fibrosis as via standard sweat chloride/phenotypic features/genotyping

4. Stable lung disease as evidenced by no change in respiratory medications or change in forced expiratory volume in 1 second (FEV1) of >15% from baseline over the preceding 4 weeks prior to enrollment

5. Baseline FEV1 >70% of predicted.

6. No use of supplemental oxygen

7. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial

8. Subjects must be willing and able to comply with scheduled visits and other trial procedures. Subjects without CF must meet all of the following inclusion criteria to be eligible for

enrollment:

1. Subjects must be at least 18 years of age;

2. Non-smokers (<10 pack year history and no active smoking in the past year);

3. Baseline FEV1 >70% of predicted.

4. No use of supplemental oxygen or clinically significant lung disease

5. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial

6. Subjects must be willing and able to comply with scheduled visits and other trial procedures.

Exclusion Criteria:

1. Active or past smokers with less than 1 years since quitting or >10 pack-year smoking history

2. Co-existent asthma (as evidenced by either clinical diagnosis, chronic oral steroid use, or marked broncho-reactivity on pulmonary function testing)

3. Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications including

• Occupation (past or present) of machinist, welder, grinder;
• Injury to the eye involving a metallic object
• Injury to the body by a metallic object (bullet, BB, shrapnel)
• Presence of a cardiac pacemaker or defibrillator
• Presence of aneurysm clips
• Presence of carotid artery vascular clamp
• Presence of neurostimulator
• Presence of insulin or infusion pump
• Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of UNCH or is older than 10 years)
• Bone growth or fusion simulator
• Presence of cochlear, otologic or ear implant
• Any type of prosthesis (eye, penile, etc.)
• Artificial limb or joint
• Non-removable electrodes (on body, head or brain)
• Intravascular stents, filters or coils
• Shunt (spinal or intraventricular)
• Swan-ganz catheter
• Any implant held in place by a magnet
• Transdermal delivery system (e.g. Nitro)
• Intrauterine Device (IUD) or diaphragm
• Tattooed makeup (eyeliner, lips, etc.) or tattoos covering >25% of body surface area
• Body piercings (MUST BE REMOVED BEFORE MRI)
• Any metal fragments
• Internal pacing wires
• Metal or wire mesh implants
• Hearing aid (REMOVE BEFORE MRI)
• Dentures (REMOVE BEFORE MRI)
• Claustrophobia

4. Unable to tolerate inhalation of gas mixture

5. Any changes in medications that may affect CF lung disease in the past 14 days, including any experimental therapies

6. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.

7. Pregnancy; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MRI scan, prior to the MRI scan.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Lung Diseases

Intervention

Drug:
• Hyperpolarized Xenon gas
Hyperpolarized Xenon gas Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen) Administration: By mouthpiece attached to a single use Tedlar bag. Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe. Frequency: 10-minute interval between doses.
• PFP
Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas) Administration: Full-face disposable ventilation mask and a standard Douglas Bag system. Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition. Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.

Locations

Country	Name	City	State
United States	The University of North Carolina at Chapel Hill	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	Cystic Fibrosis Foundation

Country where clinical trial is conducted

United States, 

References & Publications (1)

McCallister A, Chung SH, Antonacci M, Z Powell M, Ceppe AS, Donaldson SH, Lee YZ, Branca RT, Goralski JL. Comparison of single breath hyperpolarized (129) Xe MRI with dynamic (19) F MRI in cystic fibrosis lung disease. Magn Reson Med. 2021 Feb;85(2):1028-1038. doi: 10.1002/mrm.28457. Epub 2020 Aug 8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Volume of unventilated lung area after a single 129Xe inhalation and after each inhalation cycle with PFP	Primary comparison will be the VDP with Xenon (single breath) and after first PFP inhalation cycle (3 breaths of PFP)	1 hour
Secondary	Signal-to-noise (SNR) of each modality	Assessment of the quality of signal achieved with each modality	20 minutes
Secondary	Rate constant describing wash-in and wash-out of PFP	change in ventilated areas of the lung over time when administered PFP	15 minutes
Secondary	Correlation between VDP identified by each modality and spirometry and Lung Clearance Index (LCI)	Comparison of VDP to two standard metrics of lung function, spirometry and LCI	2 hours